COSCIENS Biopharma vs DSwiss: revenue, profit, margins and growth compared
COSCIENS Biopharma brought in $7.5M of revenue in fiscal 2025, DSwiss $2.9M in fiscal 2025. Revenue changed by -21.8% at COSCIENS Biopharma and -6.2% at DSwiss on the year before, so DSwiss grew faster. COSCIENS Biopharma kept -138.1% of its revenue as net profit, DSwiss -2.6%. Free cash flow was -$9.2M at COSCIENS Biopharma and -$135.3K at DSwiss.
Fiscal years as each company reports them; the two may end in different months.
Questions about COSCIENS Biopharma and DSwiss
Which is bigger by revenue, COSCIENS Biopharma or DSwiss?
COSCIENS Biopharma is bigger by revenue: $7.5M in fiscal 2025, against $2.9M for DSwiss in fiscal 2025.
Which keeps more of its revenue as profit, COSCIENS Biopharma or DSwiss?
COSCIENS Biopharma had a net margin of -138.1% in fiscal 2025; DSwiss had -2.6% in fiscal 2025.
Which grew revenue faster, COSCIENS Biopharma or DSwiss?
In their latest fiscal years revenue changed by -21.8% at COSCIENS Biopharma and -6.2% at DSwiss.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.